key: cord-0280540-yueir7l1 authors: Letizia, M.; Kaufmann, U.; Wang, Y.-H.; Gerbeth, L.; Sand, A.; Brunkhorst, M.; Ziegler, J. F.; Boettcher, C.; Schlickeiser, S.; Zapata, M. F.; Stauderman, K.; Kunkel, D.; Siegmund, B.; Feske, S.; Weidinger, C. title: Store-Operated Calcium Entry Controls Innate and Adaptive Immune Cell Function in Inflammatory Bowel Disease date: 2021-09-15 journal: nan DOI: 10.1101/2021.09.11.21263401 sha: c3e9e3c006f698f4afec272a87a86051555778b1 doc_id: 280540 cord_uid: yueir7l1 Objective: Inflammatory bowel disease (IBD) is characterized by dysregulated intestinal immune responses and constitutes a major clinical challenge in need of new treatment modalities to improve patient care. Store-operated Ca2+ entry (SOCE) is the predominant Ca2+ influx pathway in T cells and other immune cells, regulating many of their functional properties. It is currently unknown whether the pharmacologic blockade of SOCE represents a suitable drug-target for IBD treatment. Design: Using mass and flow cytometry the effects of SOCE inhibition on lamina propria (LP) immune cells of patients with ulcerative colitis (UC) and Crohn's disease (CD) were investigated.Primary organoid cultures served to study the impact of SOCE inhibition on the function, differentiation and survival of intestinal epithelial cells (IEC). T cell transfer models of colitis were applied to examine how the genetic or pharmacologic ablation of SOCE affects the clinical course of IBD in mice. Results: We observed that the LP of IBD patients is characterized by an enrichment of innate lymphoid cells (ILC), CD4+ and CD8+ effector- as well as T regulatory cells producing IL-17 and TNF. The pharmacologic inhibition of SOCE attenuated the production of pathogenic cytokines including IL-2, IL-4, IL-6, IL-17, TNF and IFN{gamma} by human colonic T cells and ILC, reduced the production of IL-6 by B cells and the production of IFN{gamma} by myeloid cells, without affecting the viability, differentiation and function of primary IEC. T cell-specific genetic deletion of the SOCE signaling components Orai1, Stim1 or Stim2 revealed that the magnitude of SOCE correlates with the function of T cells and intestinal inflammation in mice. Moreover, the pharmacologic inhibition of SOCE alleviated the clinical course of colitic mice. Conclusion: Our data suggest that SOCE inhibition may serve as a new pharmacologic strategy for treating IBD. Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal (GI) tract that manifests predominantly as two related disease entities, ulcerative colitis (UC) and Crohn's disease (CD). Both forms of IBD are associated with diarrhea, abdominal pain, fatigue as well as the development of colorectal cancer in patients with longstanding colitis and the development of fistulae and stricturing disease in patients with CD (1) . Whereas UC predominantly affects the colon and is characterized by a superficial inflammation of the LP, CD can involve the entire GI tract and cause trans-mural inflammation. New single cell technologies such as single cell RNA-sequencing and mass cytometry have greatly advanced our pathophysiologic understanding of IBD (2, 3) as they have helped to better delineate the intestinal immune cell composition of IBD patients that drive intestinal inflammation. The LP of UC patients is characterized by a significant enrichment of TNFα producing CD8 + effector T cells (2) , IL-17 producing effector memory CD4 + T cells and an expansion of T regulatory (Treg) cells producing inflammatory cytokines (3) . HLA-DR + CD56 + granulocytes as well as TNFα− and INFγ−producing B cells are increased in the mucosa of CD patients (3) . Despite these findings, the immune cell composition, signaling cascades and the cytokine networks controlling inflammation in therapy-refractory IBD remain incompletely understood. Recent advances that have revolutionized IBD treatment include blocking antibodies against pro-inflammatory cytokines such as TNFα (e.g. infliximab or adalimumab), IL-12 and IL-23 (ustekinumab) and against integrins such as vedolizumab (4) . Nevertheless, intestinal and colonic resections are still frequently required in patients with therapy-refractory IBD, and novel treatment modalities are urgently needed to improve IBD outcomes. SOCE is the predominant Ca 2+ influx pathway in most immune cells and is required for the activation, differentiation and function of murine and human lymphocytes including B, NK and T cells. Stimulation of the T cell receptor (TCR) leads to production of the second messenger inositol-1,4,5 triphosphate (IP 3 ), which triggers a transient release of Ca 2+ from endoplasmic reticulum (ER) Ca 2+ stores through IP 3 receptors into the cytoplasm (5) . The concomitant reduction of Ca 2+ concentrations in the ER is sensed by stromal interaction molecules (STIM) 1 and STIM2 in the ER membrane, which are subsequently activated and translocate to the plasma membrane (6) . Activated STIM1 and STIM2 bind to ORAI1 and its homologues ORAI2 and ORAI3, which form the pore of the Ca 2+ releaseactivated Ca 2+ (CRAC) channel. SOCE through CRAC channels causes a sustained elevation of intracellular Ca 2+ levels (7, 8) , which is required for the activation of numerous Ca 2+ -dependent enzymes including calcineurin, calmodulin kinases or Erk1/2 and transcription factors such as NF-κΒ, CREB and NFAT (9) (10) (11) . SOCE is essential for the transcription of cytokines including IL-2, IFNγ and TNFα by T cells and other immune cells. In addition, SOCE regulates several metabolic pathways such as glycolysis and mitochondrial respiration, thereby controlling lymphocyte proliferation and All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.11.21263401 doi: medRxiv preprint 4 effector functions (11) (12) (13) . The pathophysiological importance of SOCE for immune function is emphasized by patients with loss-of-function mutations in STIM1 or ORAI1 genes, who suffer from combined immunodeficiency with recurrent infections (14) (15) (16) (17) (18) . On the other hand, genetic or pharmacological inhibition of SOCE suppresses pro-inflammatory T cell functions and autoimmunity in animal models of multiple sclerosis and colitis (19) (20) (21) (22) . Given the critical role of SOCE in immune cells, we hypothesized that pharmacologic blockade of SOCE might attenuate the pro-inflammatory function of lymphoid and myeloid immune cells from patients with therapy-refractory IBD and therefore represent a new strategy for immune modulation. Using T cell transfer models of colitis, we show that deletion of the CRAC channel genes Stim1, Stim2 or Orai1 in T cells prevents IBD and that the severity of intestinal inflammation correlates with the level of SOCE. By applying mass cytometry (CyTOF), we characterized immune cell subsets in the colonic LP of therapy refractory IBD patients and investigated the effects of the SOCE inhibitor BTP2 on intestinal immune cell populations from IBD patients. SOCE inhibition efficiently suppressed various pro-inflammatory functions of human T cells in a dosage dependent manner, inhibited the function of innate lymphoid cells (ILC) and, to a lesser degree, the function of myeloid cells and B cells. Importantly, treatment with the BTP2 had no detectable effects on the epithelial barrier functions of primary human and murine intestinal epithelial cells (IEC) in vitro. Treatment of mice in which IBD had been induced by adoptive T cell transfer with the selective SOCE inhibitor CM4620 attenuated the clinical course of colitis, which was associated with reduced neutrophil infiltration of the LP and decreased IFNγ and TNFα production by CD4 + T cells, suggesting that SOCE inhibition may be a new treatment option for IBD. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.11.21263401 doi: medRxiv preprint We had previously shown that murine T cells lacking functional ORAI1 channels have reduced SOCE, resulting in impaired production of pro-inflammatory cytokines such as IFNγ and IL-17A, which was associated with a reduced capability to induce colitis upon their adoptive transfer into lymphopenic mice (20, 22) Figure 1A) . Deletion of CRAC channel components affected SOCE in Th1, Th17 and iTreg cells to a similar degree. Because of these graded effects on SOCE, we next isolated naive CD4 + T cells from these mice and injected them into Rag1 -/host mice to induce colitis and to determine if the magnitude of SOCE determines the severity of intestinal inflammation ( Figure 1A) . comparable to wild-type T cells (Figure 1B,C) . By comparison, transfer of Orai1-deficient CD4 + T cells was associated with significantly attenuated weight-loss and disease severity. Transfer of Stim1deficient T cells did not cause weight loss and no obvious signs of intestinal inflammation were detected ( Figure 1B,C) . Flow cytometric analysis of CD4 + T cells obtained from mesenteric lymph nodes (mLN) showed similar frequencies of cells producing IFNγ, TNFα and IL-17 when we compared Stim2-deficient and wild-type T cells ( Figure 1D ). By contrast, deletion of Orai1 and Stim1 resulted in significantly reduced frequencies of IFNγ, TNFα and IL-17 producing CD4 + T cells compared to wildtype cells. The frequencies of Treg cells were significantly reduced in the absence of Orai1 -or Stim1, but not in the absence of Stim2 (Figure 1D) . These findings suggested that moderate inhibition of SOCE in Stim2-deficient CD4 + T cells has no effects on T cell function, whereas more pronounced inhibition in Orai1-or Stim1-deficient CD4 + T cells gradually suppresses inflammatory cytokine production and the differentiation of iTreg cells in vivo. To determine the magnitude of SOCE required for T cell function and iTreg development, we differentiated Orai1, Stim1, Stim2 and Stim1/Stim2- All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.11.21263401 doi: medRxiv preprint 6 expression, we found that inhibition of SOCE in murine T cells most profoundly suppresses IL-17 production followed by IFNγ production and to a lesser degree expression of Foxp3 ( Figure 1F, Supplementary Figure 1C) . These findings suggest that the amplitude of SOCE determines the fate of murine CD4 + T cells with the strongest dependence on SOCE observed in inflammatory Th17 and Th1 cells. To investigate the role of SOCE in the function of lamina propria mononuclear cells (LPMCs) and intestinal inflammation in IBD patients, we isolated LPMCs from surgical colon resectates of IBD patients and peripheral blood mononuclear cells (PBMCs) from healthy donors (HD)(Supplementary Table 1 for clinical details) and assessed Ca 2+ influx by flow cytometry after ex vivo incubation with increasing concentrations (15 -1,000 nM) of the CRAC channel inhibitor BTP2 (Figure 2A) (20, 23, 24). Treatment with BTP2 caused a dose-dependent inhibition of SOCE in CD4 + and CD8 + T cells with almost complete inhibition of SOCE inhibition at 1 µM ( Figure 2B ). 1 µM BTP2 also significantly reduced Ca 2+ influx in PBMCs of HD, specifically in CD4 + and CD8 + T cells, CD19 + B cells, CD14 + monocytes and, to a lesser degree, CD56 + NK cells (Supplementary Figure 2) , demonstrating that BTP2 is a potent inhibitor of SOCE in human gut-resident lymphocytes and PBMCs. To exclude that the observed differences in Ca 2+ influx were caused by BTP2-induced cell death of lymphocytes, we measured apoptosis of LPMCs of IBD patients after incubation with 1 µM BTP2. As shown in Supplementary Figure 3 we did not observe increased cell death in BTP2 treated LPMCs compared to untreated control cells. To determine the effects of SOCE inhibition on the function of LPMCs isolated from IBD patients, we subsequently evaluated the production of various pro-inflammatory cytokines and factors in LPMCs of 5 CD patients after BTP2 treatment (15 -1,000 nM) in vitro by mass cytometry (Figure 2C ). To examine the effects of SOCE inhibition on T cell function in a BTP2 dose-dependent manner, we applied the t-distributed stochastic linear embedding (t-SNE) algorithm and the All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. FlowSOM/ConsensusClusterPlus self-organizing map method (25), which allowed us to cluster CD45 + CD3 + LPMCs into 9 major cell subtypes (Supplementary Figure 4A-B) according to the expression of major lineage markers listed in Supplementary Table 3 . Subsequently, we compared the expression of cytokines and activation markers between LPMCs stimulated with PMA/ionomycin for 4h and samples treated with PMA/ionomycin in the presence of increasing concentrations of BTP2. Stimulation of LPMCs with PMA/ionomycin resulted in an increased of expression IL-2 in CD45 + CD3 + LPMCs, which was inhibited gradually by increasing concentrations of the CRAC channel inhibitor BTP2 (Figure 2D ). BTP2 also efficiently decreased the production of other cytokines including IFNγ, TNFα, IL-17, IL-13 and IL-4 in a dose-dependent manner ( Figure 2E ). Similar suppression of cytokine production was observed in effector and memory CD4 + and CD8 + T cells, and to a lesser extent in CD4 + IL17 + Th17 cells. The weakest effects of SOCE inhibition on cytokine production were observed in CD4 + CD25 + IL7R -Treg cells. Only IL-2, IL-17 and TNFα were suppressed by ~ 50% with the highest concentration of BTP2 (1 µM) in Treg cells, whereas the same concentration of BTP2 strongly suppressed IL-2 and IFNγ in effector and memory CD4 + and CD8 + T cells. These findings are consistent with the greater resistance of murine iTreg cells to inhibition of SOCE (Figure 1 )(5, 26) and further highlight the alternating requirements of cell-specific thresholds of SOCE signaling strength. Besides cytokines, the expression of several functional markers of LPMCs such as CD40L, FasL and PD-1 was decreased by increasing concentrations of BTP2 ( Figure 2F ) which is consistent with the known role of Ca 2+ and NFAT in their transcriptional regulation (27) (28) (29) . For other markers such as CD25, CD137 (4-1BB) or CCR7, we found a dose-dependent up regulation upon treatment with BTP2 ( Figure 2F ). Interestingly, this increase was cell type specific and did not occur in all T cell subsets. For instance, CD25 was up regulated in BTP2-treated CD4 + and CD8 + effector and memory T cells, but not in Th17 and Treg cells after pharmacologic blockade of SOCE. Similarly, CD137 was only significantly up regulated after BTP2 treatment in effector and memory CD8 + T cells. These findings suggest that cell type-specific thresholds for the effects of SOCE may exist that control the functions of different T cell subsets. To better understand the role of SOCE in other LPMC subsets besides T cells, we analyzed the expression of cytokines and functional markers in BTP2-treated CD45 + CD3 -LPMCs of the same IBD patients ( Figure 2G, Supplementary Figure 5) . Surprisingly, cytokine production by CD19 + HLA-DR + B cells was barely affected by increasing BTP2 concentrations. A slightly more pronounced suppression, especially of IFNγ and to a lesser degree of TNFα, was observed in CD11c + myeloid cells. By contrast, SOCE inhibition resulted in a significant induction of CD25 and CCR7 expression in both B cells and myeloid cells ( Figure 2G) . It is noteworthy that the findings described above in LMPCs of CD patients could be confirmed in independent experiments using LPMCs isolated from 3 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Supplementary Figure 6) . Collectively, these data demonstrate the significant effects of SOCE inhibition on pro-inflammatory cytokine expression in LP T cells, and to a lesser degree myeloid cells, of CD and UC patients and the complex, subset-dependent regulation of immune cell activation markers. After establishing BTP2 as a potent inhibitor of SOCE and the function of human LPMC, we next investigated whether the function of disease-modifying LPMC subsets in IBD patients can be modulated by pharmacologic SOCE inhibition. To address this question, we first aimed to define UCand CD-specific immune cell compositions in the LP of patients with therapy-refractory IBD, which is currently not well defined. We used the following stepwise approach: First, we compared the frequencies and functional status of immune cell subsets within LPMCs isolated from 6 patients with UC and 6 patients with CD undergoing colon resection due to refractory disease. Using mass cytometry, we compared the LPMC composition of IBD patients to that in non-inflamed colon mucosa obtained from non-IBD control patients (Supplementary Table 1 for clinical details). Isolated LPMC were stimulated with PMA/ionomycin for 4h ex vivo and analyzed by CyTOF using a panel of 37 markers (Figure 3A and Supplementary Table 2) , which allowed us to determine functional aspects of disease-specific cell subsets that drive inflammation in UC and CD. To investigate the effects of SOCE inhibition on these IBD-characterizing LPMC subsets, we stimulated LPMC in the presence or absence of a single concentration of 1µM BTP2 for which we had observed an almost complete suppression of Ca 2+ influx and cytokine production in LP T cells (Figure 2A) . For the evaluation of CyTOF data, we first performed a general high-dimensional analysis of all CD45 + cells that were clustered based on their expression of lineage markers (Figure 3 ). This was followed by in-depth analyses of CD45 + CD3 + LP T cells (Figure 4 ) and CD45 + CD3 -LPMCs ( Figure 3D . All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This analysis revealed several significant differences between LPMC populations in CD patients vs. controls, UC patients vs. controls and between CD and UC patients: Compared to LPMC from noninflamed controls, UC and CD patients both showed a significant increase in the frequencies of CD4 + CD45RO + effector T cells (cluster 15), CD8 + CD45RA + naive T cells (cluster 17) and CD4 + CD25 + IL7R -Treg cells (cluster 20) ( Figure 3E ). Increased Treg frequencies are consistent with previous reports (30, 31) and are in line with the hypothesis that Treg numbers are elevated in the LP of IBD patients as a compensatory immune-regulatory mechanism to control the ongoing inflammation. We also observed differences specific to UC patients: Thus, the frequencies of CD38 + IgA + (cluster 11) and CD38 + IgM + (cluster 13) plasma B cells were significantly reduced in UC patients compared to CD patients and non-IBD controls, whereas their CD38 + (cluster 8), CD38 + HLA-DR + IgA -(cluster 9) and CD38 + IgM -(cluster 12) B cells were significantly expanded compared to noninflamed controls, suggesting a profound, UC specific dysregulation of the B cell compartment. UC patients also had significantly fewer CD4 + CD45RO + IL7R + effector memory T cells (cluster 16) and CD8 + CD45RO + effector T cells (cluster 18) compared to CD patients and controls. After defining the differences between LPMC subsets in IBD patients and controls, we next analyzed the expression levels of activation markers and cytokines in LPMC of UC, CD patients and non-inflamed controls within these cell clusters after stimulation of LPMC with PMA/ionomycin for 4h ex vivo ( Figure 3F) . Intriguingly, Treg cells (cluster 20) of both UC and CD patients produced more pro-inflammatory cytokines such as TNFα and IL-17 compared to non-inflamed controls, whereas only Treg cells of CD patients also showed increased production of IL-2. These findings are in line with a recent report by Mitsialis et al (3) . Furthermore, we observed a significant up regulation of PD-1 and CD27 on different T cell subsets of UC but not CD patients compared to controls, suggesting that T cell exhaustion might be a feature of the chronic inflammatory milieu in UC patients. Myeloid cells and B cells of both UC and CD patients were characterized by a higher expression of HLA-DR and IL-6 compared to non-inflamed controls. Overall, these findings demonstrate that the balance of effector CD4 + and CD8 + T cells in the LP of IBD patients is severely perturbed compared to non-inflamed controls. Of note, our findings highlight a specific role of PD-1 expressing exhausted T cells in UC but not CD patients. In addition, we observed profound differences in the composition of humoral and innate immune cells in the LP of UC and CD patients, with a particular involvement of CD38 + plasma cells producing IgA and IgM in CD but not UC patients. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We next aimed to determine in more detail how SOCE regulates the activation of IBD-characterizing LPMCs and their ability to produce pro-inflammatory cytokines that are implicated in the pathophysiology of UC and CD (8) . We therefore conducted separate analyses for CD45 + CD3 + T cells Table 5 ) we identified 20 subsets of cells within CD45 + CD3 + LP T cells ( Figure 4A ). UC and CD patients were both characterized by an enrichment of CD4 + IL-17 + (cluster 11), CD8 + CD45RA + IFNγ + T cells (cluster 4) and CD4 + Treg cells (cluster 20) compared to non-inflamed controls ( Figure 4A) . Unexpectedly, the frequency of CD4 + IL-4 + IL-13 + Th2 cells (cluster 13) was significantly reduced in both CD and UC compared to control samples, suggesting that these cells may not play a major pathogenic role in the maintenance of chronic inflammation in therapy-refractory IBD. UC patients harbored higher frequencies of CD4 + PD1 + (cluster 14), CD8 + PD1 + (cluster 18) and CD4 + TNFa + (cluster 15) T cells when compared to CD patients and non-IBD controls. By contrast, the frequencies of CD4 + IL7R high IL-2 + TNFα + IFNγ + (cluster 5) and CD4 + IL7R high IL-2 + TNFα + IL-17 + (cluster 6) T cells were significantly reduced in UC patients compared to CD patients and non-inflamed control samples ( Figure 4A ). Together these findings demonstrate that the composition of CD4 + and CD8 + T cell populations and their activation status is significantly perturbed in the LP of IBD patients with further differences between UC and CD patients. We next investigated how the inhibition of SOCE affects the function of the identified CD3 + T cell subsets isolated from the LP of UC and CD patients. We paid particular attention to differential effects of SOCE inhibition on specific T cells subsets in order to discriminate the individual role of SOCE in each of the described T cell subsets. Inhibition of SOCE by 1 µM BTP2 during ex vivo stimulation with PMA/ionomycin resulted in strongly reduced abundances of naive CD4 + IL-2 + T cells (cluster 3), CD4 + IL-2 + TNFa + (cluster 12) and IL-4 + IL-13 + Th2 cells (cluster 13) in UC and CD patients ( Figure 4B ,C). Moreover, the frequencies of pro-inflammatory CD4 + IL-7R + and CD8 + IL-7R + memory T cells that produced IL-2, IFNγ and TNFα (clusters 5 and 9) were significantly reduced in UC and CD patients after SOCE inhibition. Likewise, we observed a decrease in the percentages of CD4 + IL-17 + T cells (cluster 11) and CD4 + IL-7R + memory T cells producing IL-2, TNFα and IL-17 (cluster 6) in BTP2treated LPMC of UC and CD patients. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Inhibition of SOCE in LPMC isolated from UC and CD patients resulted in parallel, in a relative increase of non-activated CD4 + and CD8 + T cells (clusters 10 and 17cells) and naive CD4 + T cells Figure 4D , right panel). IFNγ and IL-2 production were similarly affected by BTP2 in UC and CD patient samples; a notable exception were Treg cells because IFNγ and IL-2 production were only significantly suppressed by BTP2 in patient samples of CD but not UC. The effects of SOCE inhibition on IL-4, IL-13 and IL-17 production were more moderate and reached significance in only a few T cell subsets in both UC and CD patients. It is noteworthy, however, that BTP2 inhibited the production of cytokines and suppressed the expression of activation markers in the IL-4 + IL-13 + Th2 subset (cluster 13) in UC patients and to a lesser degree also in CD patients, suggesting that SOCE is a potent regulator of Th2 cell function. Among surface markers, we observed a significant decrease in the expression of FasL, CD40L and PD-1 upon inhibition of SOCE, which was expected since the transcription of these molecules, like that of many of the cytokines described above, is dependent on Ca 2+ signaling and NFAT (27-29). In contrast, the increased expression of several T cell markers such as IL-7R, CD137, CD25 and CCR7 as well as the cytokine IL-23p19 in certain T cell subsets of UC and CD patients after BTP2 treatment was not anticipated. It is noteworthy that the expression of the co-stimulatory receptor CD137 (4-1BB) was differentially affected by SOCE inhibition; while it was up-regulated in BTP2-treated effector T cells, its expression decreased in Treg cells upon inhibition of SOCE. Collectively, our data demonstrate that SOCE is a potent regulator of T cell activation and function in LP T cells of both UC and CD patients as the pharmacologic blockade of SOCE effectively suppresses the production of pro-inflammatory cytokines, in CD4 + effector and memory T cells in the LP of UC and CD patients. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We next focused our analysis on characterizing the composition of non-T cell subsets within LPMC of IBD patients and non-inflamed controls and investigated the effects of SOCE inhibition on these cells. In-depth analysis of CD45 + CD3cells allowed us to define 20 cell clusters ( Figure 5A ) based on the expression of lineage markers, cytokines and functional markers described in Supplementary Tables 2 and 6. We detected an increase of IL-17 producing ILC3 cells (cluster 15) in colonic mucosa samples of UC and CD patients compared to non-inflamed tissue controls (Figure 5A) , which is in line with a recent study that had observed a larger abundance of ILC3 cells in the peripheral blood of IBD patients with active disease (3) . In addition, the frequencies of CD11c + CD11b + myeloid cells (cluster 1) were increased in UC samples and, to a lesser degree, in CD patients compared to non-inflamed controls. Interestingly, CD samples harbored increased frequencies of CD3 -CD19 -Il7R + CD25 + ILCs In analogy to our previous analyses, we subsequently analyzed how BTP2 treatment affects the expression of pro-inflammatory cytokines by non-T cells in the LP. Several subsets of activated CD19 + HLA-DR + B cells (clusters 4, 5 and 6) displayed a strong reduction of IL-6 production in samples of UC and CD patients treated with BTP2 ( Figure 5D ). In UC patients, the production of TNFα, IL-2 and IL-17 and the expression of CD40L and FasL was significantly reduced in ILCs (cluster 16) after exposure to BTP2 ( Figure 5D ). UC patients furthermore featured decreased levels of CCR7, CD27 and CD137 expression in ILC3 cells (cluster 15). In CD patients, BTP2 suppressed the production of TNFα, IL-2 and IFNγ as well as the expression of FasL by NK cells (cluster 18). Inhibition of SOCE furthermore significantly reduced the expression of IFNγ by myeloid cells of CD patients ( Figure 5D ). By contrast, the activation markers CD25, CD137, CD86 and CD137 were significantly up-regulated on CD19 + B cells (cluster 5) after BTP2 treatment. Taken together, inhibition of SOCE suppressed the expression of several inflammatory cytokines including IL-6 (B cells), TNFα All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.11.21263401 doi: medRxiv preprint 13 (ILC and NK cells) and IFNγ (myeloid and NK cells) in IBD patients, suggesting that SOCE contributes to the pro-inflammatory milieu in the LP of IBD patients generated by myeloid cells and ILCs. Compared to the pronounced effects of BTP2 on CD3 + T cells (Figure 4) , the inhibition of SOCE had more moderate effects on CD3 -LPMC, suggesting that Ca 2+ signals are more consequential for intestinal T cells than non-T cells. After establishing that genetic deletion of CRAC channel components in mouse T cells ( Figure 1 ) and . Surprisingly, very limited information is available about the physiological role of CRAC channels in IEC function (32). To investigate how SOCE inhibition affects the survival, differentiation and function of IEC, we first isolated colonic crypts from C57BL/6 wild-type mice, which were cultured ex vivo into colonic organoids or 2D organoids monolayers. Treatment of murine IEC-derived organoids with 1 µM BTP2 did not significantly impact their viability ( Figure 6A, B) . Moreover, the trans-epithelial resistance of primary murine colonic epithelial cells that were grown in in 2D layers did not change after treatment with 1 µM BTP2 compared to DMSOtreated controls ( Figure 6C ). To validate these results in human IEC, we isolated primary human epithelial crypts from surgical colon specimen of UC patients and cultured them into organoids and 2D monolayers. Treatment of human IEC organoids with 1 µM BTP2 did not affect their viability ( Figure 6D ). In analogy to our findings in murine IEC, BTP2 did not alter the trans-epithelial resistance of human IEC grown in 2D layers ( Figure 6E ). Likewise, the differentiation of human IEC was not influenced by BTP2 treatment as no significant differences in the mRNA expression of IEC differentiation markers ALPI, MUC2 and CHGA were observed compared to DMSO treated controls ( Figure 6E ). Together, these data indicate that the same concentrations of 1µM BTP2 that are sufficient to inhibit the activation and pro-inflammatory functions of LPMCs do not interfere with the differentiation, viability and barrier function of IEC. Because of the potent suppressive effects of SOCE inhibition with BTP2 on the expression of proinflammatory cytokines and activation markers by human LPMCs and the reduced ability of Orai1 and Stim1-deficient T cells to induce IBD in mice, we investigated if the systemic application of a All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.11.21263401 doi: medRxiv preprint 14 selective CRAC channel inhibitor is able to alleviate intestinal inflammation and the course of IBD in mice. In contrast to the adoptive transfer of Orai1 and Stim1-deficient T cells into Rag1 -/mice, in which T cells lack SOCE from the start of the experiment, injection of mice with a CRAC channel inhibitor starting 18 days after T cell transfer tests whether SOCE inhibition is able to alter the progression of established disease rather than preventing it ( Figure 7A ). For these experiments we used the selective CRAC channel blocker CM4620, which can be formulated for in vivo use and is currently in phase 2 clinical trials for COVID-19 associated pulmonary inflammation and acute pancreatitis (NCT04195347). Transfer of naïve CD4 + T cells induced weight loss in recipient Rag1 -/mice that were gavaged with vehicle alone, whereas mice treated with CM4620 showed moderate gain of weight ( Figure 7B ). Systemic pharmacologic inhibition of SOCE ameliorated intestinal inflammation compared to controls, although the differences in histological colitis scores did not reach statistical significance at the end of the experiment on day 49 ( Figure 7C ). We observed significantly lower numbers of neutrophils in the colon Lamina propria (CLP) of CM4620 treated mice, whereas those of CD4 + T cells were not reduced, ( Figure 7D ). Further characterization of CD4 + T cell subsets in the LP revealed that treatment with CM4620 did not result in a decrease in the frequencies of RORγt + Th17 cells and Foxp3 + Treg cells compared to control mice receiving vehicle only ( Figure 7E ). We next tested the function of CD4 + T cells isolated from the CLP and re-stimulated them ex vivo with PMA/ionomycin for 4h in the absence of CM4620. The frequencies of CD4 + T cells producing IFNγ, TNFα and IL-2 in the CLP of mice treated with SOCE inhibitor were significantly reduced compared to vehicle treated mice; moreover, cytokine levels per cell measured by MFI were significantly decreased ( Figure 7F ). Impaired IL-2 production was also observed after re-stimulation of CLP T cells with anti-CD3/CD28 for 24h (Supplementary Figure 10) . Reduced production of IFN-γ, TNF-α and IL-2 is consistent with the suppressive effects of SOCE inhibition on CD4 + T cells amongst LPMC isolated from CD but especially UC patients ( Figure 4D ). Not all cytokines were affected by CM4620 treatment (at least after ex vivo re-stimulation of CLP derived T cells) because the frequencies of IL-17A + IFN-γ + producing CD4 + T cells were normal after P/I stimulation (Supplementary Figure 10A) . Likewise, CD4 + T cells isolated from the CLP of CM4620 and vehicle treated mice produced similar amounts of IL-10 after re-stimulation with anti-CD3/CD28 for 24h ex vivo (Supplementary Figure 10B) . It is noteworthy that serum levels of IFN-γ and TNF-α were unaltered in CM4620 treated animals compared to controls, whereas IL-6 levels were significantly decreased upon SOCE inhibition ( Figure 7G ). Collectively, our data indicate that SOCE inhibition after the onset of IBD is able to attenuate intestinal inflammation, which is mediated at least partially by suppression of pro-inflammatory cytokine production, while preserving the numbers of Treg cells in the CLP. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.11.21263401 doi: medRxiv preprint We here characterize the immune cell composition in the colon LP of patients with UC and CD by mass cytometry and show that SOCE regulates the function of immune cells driving IBD pathology. We also demonstrate that inhibition of SOCE, by genetic deletion of CRAC channel genes or pharmacological inhibition, attenuates intestinal inflammation in mouse models of colitis. By contrast, exposure to the SOCE inhibitor BTP2 does not affect the function and differentiation of primary murine and human intestinal epithelial cells. Together, our data demonstrate that SOCE is an important driver of the pro-inflammatory function of immune cells in IBD and suggest that inhibition of SOCE may represent a new approach for the treatment of CD and UC patients. To characterize the immune cell composition in the colonic LP of therapy-refractory UC and CD patients compared with non-inflamed controls we used mass cytometry. Shared hallmarks of altered T cell composition in both IBD patient cohorts were an increased abundance of naive and effector CD4 + T cells and naive CD8 + T cells, whereas the frequencies of CD4 + CD45RO + IL-7R + effector memory T cells and CD8 + effector T cells were decreased. The overall frequencies of Treg cells were increased in the colonic LP of both UC and CD patients, but a significantly larger percentage of the remaining Treg cells produced TNFα and IL-17. These findings are in line with published single cell RNA sequencing data that also describe a higher expression of inflammatory cytokines in Treg cells of IBD patients (3), supporting the notion that intestinal inflammation in IBD is driven at least in part by an imbalance of effector versus regulatory T cells and altered Treg cell properties such as the production of inflammatory cytokines. Surprisingly, IL-4 and IL-13 producing Th2 cells were significantly reduced in both UC and CD, suggesting that Th2 cells may not be the main source of these cytokines in IBD, reminiscent of a predominant production of IL-4 and IL-13 by NKT cells in allergen-induced airway hyper-reactivity (33). In the B cell compartment, we observed a significant increase in the number of cells producing IL-6 and a reduction of CD38 + IgA + cells in both UC and CD patients. The depletion of B cells producing IgA, which is required for the opsonization and neutralization of pathogenic bacteria in the gut, is likely to contribute to IBD in both UC and CD patients, which is also supported by the fact that patients with common variable immunodeficiency and IgA deficiency are prone to develop IBDlike inflammatory enteropathies in 4-10% of cases (34, 35). Besides these commonalities between both IBD patient cohorts, UC and CD patients also featured several entity-specific differences in their LPMC composition: Thus, the colonic LP of UC patients, but not CD patients, was infiltrated with PD1 expressing CD4 + and CD8 + effector T cells, CD4 + effector memory T cells and Treg cells, which points to a chronic activation of these T cells, potentially due to translocation of intestinal antigens into the LP. Expression of the inhibitory receptor PD1 on antigen All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. activated T-cells in UC patients might thereby represent an attempt to maintain immune tolerance and to limit excessive T cell responses. Abu-Sbeih et al. recently reported a significantly higher rate of adverse gastrointestinal effects including diarrhea and colon perforation in 41% of IBD patients receiving checkpoint inhibitors compared to 11% in non-IBD patients (36). Our finding that the frequencies of PD1 + T cells are significantly increased in the colonic LP of UC patients provides a potential explanation for this clinical observation and cautions against the use of checkpoint inhibitors such as Nivolumab or Pembrolizumab in IBD patients because of their potential to induce severe flairs in UC patients. In line with the concept of a partially exhausted T cell phenotype due to chronic inflammation in UC patients, the production of the inflammatory cytokines IFNγ and IL-6 and the expression of the NFAT target CD103 (ITGAE) (37) were reduced both in effector and effector memory CD4 + T cells of UC patients, when compared to non-inflamed control samples and especially compared to CD patients. In contrast to UC patients, the immune cell landscape in the LP of CD patients was mainly characterized by high frequencies of CD38 + B cell clusters producing IgM or IgA as well as IFNγ-producing NK cells and IL7R-expressing CD4 + and CD8 + memory T cells, suggesting that these cells contribute to disease pathology in CD patients. The production of cytokines by immune cells in the LP is an important pathogenic driver of intestinal inflammation in UC and CD. In CD, IFNγ and IL-17/IL-22 generated by Th1 and Th17 cells were early on described as dominant cytokines potentially involved in disease pathogenesis, whereas the development of UC has been classically linked to high levels of IL-4 and IL-13 produced by T cells and NKT cells (38). Remarkably, our mass cytometric data did not find a predominance of IL-4 and IL-13 in the LP of UC patients but we instead mainly detected cells producing the pro-inflammatory cytokines IFNγ, TNFα and IL-6 that are known to be present in both forms of IBD (38). Intriguingly, we did not observe significant differences in the expression levels of pro-inflammatory cytokines on a single cell basis in LPMC isolated from surgical colon specimen of CD and UC patients when compared to non-inflamed controls, but we observed a higher frequency of cells expressing proinflammatory cytokines instead. However, we used a strong stimulus (PMA plus ionomycin) to induce cytokine production, which may also mask differences in cytokine production by LPMC in inflamed and non-inflamed regions. Only Treg cells isolated from inflamed lesions of CD and UC patients showed significantly increased expression of IL-17 and TNFα relative to Treg cells from non-inflamed control patients. The expression of the inflammatory cytokines described above is regulated by Ca 2+ dependent transcription factors including most prominently NFAT (10) . Given the important role of these All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.11.21263401 doi: medRxiv preprint cytokines in IBD pathogenesis, we investigated how inhibition of SOCE as the main Ca 2+ influx pathway in immune cells affects cytokine production. Using the CRAC channel inhibitor BTP2 we here demonstrate that SOCE is required for the production of many inflammatory cytokines including IL-2, Increasing concentrations of BTP2 resulted in a dose-dependent suppression of cytokine production in CD4 + and CD8 + effector and effector memory T cells, Th17 cells as well as Treg cells isolated from the LP of IBD patients. The most Ca 2+ dependent cytokines were IL-2 and IFNγ, followed by TNFα and IL-17, whereas the Th2 cytokines IL-4 and IL-13 were surprisingly insensitive to BTP2mediated SOCE inhibition. When we compared the effects of BTP2 on cytokine production by a variety of colonic T cell subsets, we observed significant reductions in the expression of IL-2, TNFα and IFNγ in both CD and UC patients. A more selective suppression of IL-4 and IL-13 production by BTP2 was found in UC patients. IL-17 production was significantly suppressed by BTP2 only in T cells of CD patients and interestingly only in CD4 + T cell subsets that also expressed TNFα. The To investigate whether the suppressive effects of SOCE inhibition on the ex vivo production of proinflammatory cytokines by LPMCs isolated from UC and CD patients translate into attenuated IBD severity in vivo, we used a murine T cell transfer model of IBD. Whereas naïve CD4 + T cells of wildtype mice induced colitis in lymphopenic host mice, deletion of Stim1 in CD4 + T cells and, to a lesser degree, Orai1 attenuated IBD severity, whereas deletion of Stim2 had no significant protective effect. The degree of IBD attenuation correlated with the degree of reduced production of IFNγ, IL-17A and TNFα by T cells isolated from the mLN of mice. The deletion of Stim2, Orai1, Stim1 and Stim1/Stim2 together in T cells results in progressively more pronounced defects in SOCE and, consequently, the expression of IFNγ by Th1 cells and IL-17A by Th17 cells in vitro. Importantly, the production of IFNγ and IL-17A was almost abolished in Orai1-deficient T cells despite substantial residual SOCE, All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.11.21263401 doi: medRxiv preprint demonstrating that incomplete suppression of SOCE is sufficient to strongly attenuate inflammatory cytokine production. By contrast, the differentiation of induced Foxp3 + iTreg cells in vitro was less affected in Orai1-deficient T cells. Only Stim1-or Stim1/Stim2-deficient T cells with strongly reduced or abolished SOCE displayed severe defects in the differentiation of iTreg cells in vitro. These data indicate that effector Th1 and Th17 cells require strong Ca 2+ influx for the production of pro- These data suggest that a therapeutic window exists for the inhibition of pro-inflammatory effector T cells without compromising the tolerogenic function of Treg cells. The concept of different SOCE thresholds in pro-inflammatory effector and regulatory T cells may extent to human immune cells. Thus, we observed that the production of IFNγ, IL-2 and other cytokines was reduced by > 50% using BTP2 in the sub-micromolar range in CD4 + effector and memory T cells of CD and UC patients. By contrast, a concentration of 1 µM BTP2 was required for a > 50% reduction of IL-17 and TNFα production by Treg cells. Moreover, cytokine production by B cells and myeloid cells was not or only moderately affected by SOCE inhibition even after exposure to high concentrations of BTP2. The molecular mechanisms controlling these differential SOCE requirements in pro-inflammatory T cells versus other immune cell subsets require further study as they might offer the opportunity to selectively control the function of specific immune cell subsets. Collectively, our data suggest that SOCE inhibition might represent an effective treatment of IBD due its preferential effects on the proinflammatory function of T cells. To investigate whether pharmacologic inhibition of CRAC channel function is an effective and safe approach to IBD treatment, we tested the effects of a systemic application of the CRAC channel inhibitor CM4620 in a murine adoptive T cell transfer model of IBD. At serum concentrations equivalent to the IC 50 for inhibition of human T cell function in vitro, we observed reduced weight loss, neutrophil inflammation of the LP and production of IFNγ and TNFα by LP T cells, whereas the frequencies of Treg cells and the amount of secreted IL-10 were not altered in the LP of animals after blockade of SOCE. These results indicate that SOCE inhibition attenuates IBD severity even when treatment is started after disease initiation and administered systemically. This is significant given the fact that SOCE is the source of Ca 2+ signals in many non-excitable cell types, including intestinal All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The SOCE inhibitor CM4620 is currently tested in clinical trials as a novel treatment option for acute pancreatitis (NCT04195347) and COVID-19 pneumonia (NCT04345614). In patients with acute pancreatitis, CM4620 attenuated inflammation as evident from reduced pancreatic edema, acinar cell vacuolization, intra-pancreatic trypsin activity, cell death signaling and acinar cell death. CM4620 also decreased suppressed neutrophil functions and cytokine production by human peripheral blood mononuclear cells (45). In a randomized, controlled, open-label study in patients suffering from COVID-19-associated pneumonia, CM4620 treatment improved outcomes in patients with severe COVID-19 and had a favorable safety profile (47). These data suggest that SOCE inhibition is well tolerated and effective in patients with severe pulmonary and pancreatic inflammation. Both studies were limited by the small numbers of the patients treated with the CRAC channel inhibitor, and by the relatively short duration of treatment. Therefore, the efficacy and safety of long-term, systemic CRAC channel inhibition in chronic inflammatory diseases such as CD and UC remains to be studied. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All mass and flow cytometric data sets are available from the corresponding authors on reasonable request that does not include confidential patient information. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. Cells were labeled with 2 µM Fura-2 AM (Life Technologies) for 30 min in cell culture medium and All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Penicillin-Streptomycin (ThermoFisher Scientific) containing 20 ng/ml phorbol 12-myristate 13-acetate All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2) for bead-based compensation of mass cytometry. For each channel assessed in the panel described above, one drop of OneComp eBeads was loaded in a well of a v-bottom 96 well plate (Corning) and individually stained with 1 µg of the corresponding metal-labeled antibody for 30 min at room temperature. After staining, individual beads were washed three times in staining buffer and afterwards pooled in a single tube and washed once in PBS (ThermoFisher Scientific). Beads were then fixed in 1.6% methanol-free formaldehyde solution (ThermoFisher) for 1 h at room temperature. After fixation, beads were washed twice in staining buffer and twice in Maxpar water. Beads were resuspended in 300 µL of Maxpar water previous CyTOF acquisition. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.11.21263401 doi: medRxiv preprint Data analysis of mass cytometry data. The Cytobank software package (www.cytobank.org) was used for initial manual gating on single cells and for de-barcoding of pooled samples. FCS files of debarcoded single-cells were exported and further compensated for signal spillover using the R Software (3.6.0, Bioconductor 9) and by applying the CATALYST package and arcsinh transformation (scale factor 5) prior to data analysis. Compensated files were then gated on CD45 + , CD45 + CD3 + or CD45 + CD3cells and t-SNE maps of each pre-gated cell population were generated according to the expression of markers listed in Supplementary Table 3-6 by using the Cytobank Software. Subsequently, FCS files containing the t-SNE embedding as additional two parameters were exported from Cytobank and the clustering analysis was performed using the FlowSOM/ConsensusClusterPlus package on R (3.6.0, Bioconductor 9) (Supplementary Fig. 7) . Cell clusters of LPMCs were identified after visual inspection of t-SNE plots and functional interpretation of heat maps generated by Crypt Isolation and culture. Establishment and maintenance of murine and human spheroid cultures from the colon epithelium were obtained as described previously (49-51). In brief, colons from C57B/6 wild-type mice were opened longitudinally, cut into small pieces, and washed with cold phosphatebuffered saline (PBS; Gibco; Life Technologies, Carlsbad, USA). Human intestinal mucosa was isolated by removing the muscle and fat tissue from colon resectates. The tissue was then cut into small (1-2 mm) stripes and washed with cold PBS. Intestinal fragments were washed repeatedly with All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. nM human gastrin I] (all from Sigma)). 10 µM Y-27632 (Abmole Bioscience, Houston, USA) was added to the culture medium for the first two days of culture after isolation or passaging. Fresh culture medium was added every other day and spheroids were passaged once a week at a 1:6 splitting ratio. For passaging, Matrigel was scraped off to collect organoids in a 15-ml conical tube. Organoids were digested into single cells in 1 ml TrypLE (Gibco) for 5 minutes at 37°C, embedded in Matrigel and seeded into a 24-well plate. Resazurin Viability Assay. Spheroids were passaged, embedded in Matrigel and seeded into 96well plates at a density of approx. 100 organoids in 8 µl Matrigel per well. Organoids were cultured in spheroid culture medium for 5 days. 10 µM Y-27632 was added for the first two days of culture. To induce differentiation, WRN-CM, nicotinamide, and SB202190 were withdrawn from the medium and 100 ng/ml recombinant noggin (Peprotech), 500 ng/ml recombinant human R-Spondin (R&D Systems, Wiesbaden, Germany) and 5 µM DAPT (Selleckchem, Houston, USA) were added as described previously (49). Initial organoid viability was assessed with resazurin sodium salt (Sigma) once before All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.11.21263401 doi: medRxiv preprint 30 changing to differentiation medium. Resazurin was added to every well at a working concentration of 0.25 µg/ml and the culture was incubated in the dark at 37°C for one hour. Subsequently, the culture medium was transferred to a black flat clear-bottom 96-well plate and fluorescence was measured at 560 nm excitation and 590 nm emission with a SpectraMax Gemini EM Microplate Reader (Molecular Devices, San Jose, USA). Wells with organoid culture were washed with PBS and fresh medium was added. Culture was continued at 37°C and viability was measured with resazurin as described above on the indicated days of culture. The medium was supplemented with 1 µM BTP2 starting from day 2 of differentiation. Organoids were cultured until a stable TEER was reached, differentiation was induced as described above and BTP2 (1µM), TNF-α (10ng/ml) and IFNγ (10ng/ml) were added as indicated. anti-CD28 (clone 37.51,obtained from BioXCell) for 3 days in the presence of the following cytokine cocktails for differentiation into Th1: 10 ng/ml IL-12 (PeproTech) and 2 µg/ml anti-IL-4 (eBioscience), Th17: 20 ng/ml IL-6 (PeproTech), 0.5 ng/ml human TGF-β1 (PeproTech), 2 µg/ml anti-IL-4 and 2 µg/ml anti-IFNγ (eBioscience), or iTreg: 2.5 ng/ml TGF-β1 (PeproTech) in IMDM (Cellgro) containing 2 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Histopathologic scoring of intestinal inflammation in mice. 8 weeks after induction of T cell transfer colitis, colon sections were fixed in 4% paraformaldehyde, embedded in paraffin and stained with haematoxylin and eosin (H&E) using standard protocols. Histology sections were scored by two independent researchers in a blinded fashion using the following grading system: 0: no changes; 1: minimal scattered mucosal inflammatory cell infiltrates, with or without epithelial hyperplasia; 2: mild scattered to diffuse inflammatory cell infiltrates, sometimes extending to the submucosa and associated with erosions, with mild epithelial hyperplasia and minimal to mild mucin depletion from goblet cells; 3: mild to moderate inflammatory cell infiltrates, sometimes trans-mural, often associated with ulceration, with moderate epithelial hyperplasia and mucin depletion; 4: marked inflammatory cell infiltrates that were often transmural and associated with ulceration, with marked epithelial hyperplasia All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.11.21263401 doi: medRxiv preprint and mucin depletion; 5: marked transmural inflammation with severe ulceration and loss of intestinal glands. Colon tissue of mice was opened longitudinally by a curved scissor and cut into pieces around 0.5 to 1cm, colon bits were predigested with pre-digestion buffer (5mM EDTA and 1mM DTT in HBSS buffer without calcium) for 15 minutes. Colon bits were then washed, further minced and digested with digestion buffer (1mg/mL collagenase IV and 0.1mg/mL DNase-I in HBSS with 5% FBS) in 37C shaker at a speed of 225rpm for 45 minutes. Cells were then isolated using a 40/75% discontinuous Percoll gradient, the middle layer was collected, washed, and re-suspended in RPMI1640 with 2% of fetal bovine serum. Cells were counted using hemocytometer. Cytometry bead assay. For measuring the cytokine production by T cells in colon, colon lamina propria derived total lymphocytes were stimulated with 0.5ug/mL anti-CD3 (clone 145-2C11, BioXcell) for 24 hours, supernatant was collected and cytokine levels were measured using a cytometry bead assay (BD Bioscience). Cytokines levels in serum from host mice were also measured using a Th1/Th2/Th17 BCA Kit (Cat 560485, BD Bioscience) as instructed by vendor. Positive and negative controls were analyzed simultaneously. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.11.21263401 doi: medRxiv preprint preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetu All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetu All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetu All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetu The preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetu All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetu All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.11.21263401 doi: medRxiv preprint preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.11.21263401 doi: medRxiv preprint Data are the mean ± SEM of 10 control and 9 CM4620 treated mice. Statistical analyses in panels D-G by unpaired student's t-test: ***p<0.001 **p<0.01 *p<0.05. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 15, 2021. ; https://doi.org/10.1101/2021.09.11.21263401 doi: medRxiv preprint Translating Immunology into Therapeutic Concepts for Inflammatory Bowel Disease Single-cell atlas of colonic CD8(+) T cells in ulcerative colitis. Nature medicine Single-Cell Analyses of Colon and Blood Reveal Distinct Immune Cell Signatures of Ulcerative Colitis and Crohn's Disease Targeting immune cell circuits and trafficking in inflammatory bowel disease IP3 receptors: some lessons from DT40 cells STIM is a Ca2+ sensor essential for Ca2+-store-depletion-triggered Ca2+ influx Orai1 is an essential pore subunit of the CRAC channel CRAC Channels and Calcium Signaling in T Cell-Mediated Immunity STIM-and Orai-mediated calcium entry controls NF-κB activity and function in lymphocytes NFAT control of immune function: New Frontiers for an Abiding Trooper Calcium regulation of T cell metabolism. Current opinion in physiology Store-Operated Ca(2+) Entry Controls Clonal Expansion of T Cells through Metabolic Reprogramming Calcium Signaling Controls Pathogenic Th17 Cell-Mediated Inflammation by Regulating Mitochondrial Function Diseases caused by mutations in ORAI1 and STIM1 STIM1 mutation associated with a syndrome of immunodeficiency and autoimmunity. The New England journal of medicine Antiviral and regulatory T cell immunity in a patient with stromal interaction molecule 1 deficiency STIM1-mediated calcium influx controls antifungal immunity and the metabolic function of non-pathogenic Th17 cells preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.